| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.042 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.041 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |